Literature DB >> 24099430

A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses.

Vandana Moudgil1, Davender Redhu, Suman Dhanda, Jasbir Singh.   

Abstract

Aflatoxins are food-borne secondary fungal metabolites that are hepatotoxic, hepatocarcinogenic, and mutagenic. Urinary and serum biomarkers are more efficient in reflecting dietary exposure to aflatoxin B₁ (AFB₁) than other methods such as food sampling and dietary questionnaires. Chronic infection of the hepatitis B virus (HBV) and dietary exposure to AFB₁ are the major risk factors in a multifactorial etiology of hepatocellular carcinogenesis, raising the possibility of a synergistic interaction between 2 agents. These effects are due to the formation of DNA and protein adducts and lipid peroxidation. Most patients with hepatocellular carcinoma and HBV infection had prevalent GC → TA transversion mutation at the third position of codon 249 of the p53 gene. The HBx protein of HBV also promotes cell cycle progression, increases the expression of telomerase reverse transcriptase, inactivates negative growth regulators, and binds to and inhibits the expression of p53 (antiapoptotic activity) and other tumor suppressor genes and senescence-related factors. Some reports also evidence the role of hepatitis C virus in the pathogenesis of HCC. Inhibitors of AFB₁ adducts are found to be potent chemoprotective agents against AFB₁-induced HCC. This review focuses on the interaction of aflatoxin, HBV, and hepatitis C virus in the development of HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24099430     DOI: 10.1615/jenvironpatholtoxicoloncol.2013007166

Source DB:  PubMed          Journal:  J Environ Pathol Toxicol Oncol        ISSN: 0731-8898            Impact factor:   3.567


  20 in total

1.  Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers.

Authors:  Yu-Ju Chu; Hwai-I Yang; Hui-Chen Wu; Jessica Liu; Li-Yu Wang; Sheng-Nan Lu; Mei-Hsuan Lee; Chin-Lan Jen; San-Lin You; Regina M Santella; Chien-Jen Chen
Journal:  Int J Cancer       Date:  2017-05-26       Impact factor: 7.396

Review 2.  Hepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.

Authors:  Kerstin Herzer; Guido Gerken; Thomas G Hofmann
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

3.  Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E.

Authors:  Ning Ma; Yanqi Hou; Heidi Coia; Marcin D Dyba; Ying Fu; M Idalia Cruz; Carlos Benitez; Garrett T Graham; Justine N McCutcheon; Yun-Ling Zheng; Bing Sun; Bhaskar V Kallakury; Junfeng Ma; Hong-Bin Fang; Deborah L Berry; Vinona Muralidaran; Fung-Lung Chung
Journal:  Cancer Prev Res (Phila)       Date:  2018-08-21

Review 4.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

5.  Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption.

Authors:  Yu-Ju Chu; Hwai-I Yang; Hui-Chen Wu; Mei-Hsuan Lee; Jessica Liu; Li-Yu Wang; Sheng-Nan Lu; Chin-Lan Jen; San-Lin You; Regina M Santella; Chien-Jen Chen
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

6.  Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma.

Authors:  C Zhang; C Li; X Chen; Y Zhou; B Yin; R Ni; Y Zhang; J Liu
Journal:  Clin Transl Oncol       Date:  2017-06-06       Impact factor: 3.405

7.  Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma.

Authors:  Linlin Yang; Baoying Hu; Yixin Zhang; Songlin Qiang; Jin Cai; Wei Huang; Chen Gong; Tingting Zhang; ShuSen Zhang; Pan Xu; Xuming Wu; Jibin Liu
Journal:  Med Oncol       Date:  2015-03-21       Impact factor: 3.064

8.  The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.

Authors:  Baoying Hu; Yicheng Xiong; Runzhou Ni; Lixian Wei; Dawei Jiang; Gang Wang; Di Wu; Tianxin Xu; Fengbo Zhao; Mingyan Zhu; Chunhua Wan
Journal:  Mol Cell Biochem       Date:  2014-08-01       Impact factor: 3.396

9.  Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma.

Authors:  Weidong Shi; Wei Huang; Yuyan Chen; Shusen Zhang; Pan Xu; Xiaoling Gu; Hui Fan; Jian Xu; Yongmei Chen; Runzhou Ni; Cuihua Lu; Xiubing Zhang
Journal:  Tumour Biol       Date:  2016-02-05

10.  Cold-inducible RNA-binding protein promotes the development of liver cancer.

Authors:  Toshiharu Sakurai; Norihisa Yada; Tomohiro Watanabe; Tadaaki Arizumi; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Jun Fujita; Masatoshi Kudo
Journal:  Cancer Sci       Date:  2015-03-03       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.